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Abstract 
Background: Niemann–Pick disease type C (NPC) is a rare, progressive, neurodegenerative disease associated with 
neurovisceral manifestations resulting from lysosomal dysfunction and aberrant lipid accumulation. A multicentre, 
prospective observational study (Clinical Trials.gov ID: NCT02435030) of individuals with genetically confirmed NPC1 
or NPC2 receiving routine clinical care was conducted, to prospectively characterize and measure NPC disease pro‑
gression and to investigate potential NPC‑related biomarkers versus healthy individuals. Progression was measured 
using the abbreviated 5‑domain NPC Clinical Severity Scale (NPCCSS), 17‑domain NPCCSS and NPC clinical database 
(NPC‑cdb) score. Cholesterol esterification and heat shock protein 70 (HSP70) levels were assessed from peripheral 
blood mononuclear cells (PBMCs), cholestane‑3β,5α‑,6β‑triol (cholestane‑triol) from serum, and unesterified cho‑
lesterol from both PBMCs and skin biopsy samples. The inter‑ and intra‑rater reliability of the 5‑domain NPCCSS was 
assessed by 13 expert clinicians’ rating of four participants via video recordings, repeated after ≥ 3 weeks. Intraclass 
correlation coefficients (ICCs) were calculated.
Results: Of the 36 individuals with NPC (2–18 years) enrolled, 31 (86.1%) completed the 6–14‑month observation 
period; 30/36 (83.3%) were receiving miglustat as part of routine clinical care. A mean (± SD) increase in 5‑domain 
NPCCSS scores of 1.4 (± 2.9) was observed, corresponding to an annualized progression rate of 1.5. On the 17‑domain 
NPCCSS, a mean (± SD) progression of 2.7 (± 4.0) was reported. Compared with healthy individuals, the NPC popula‑
tion had significantly lower levels of cholesterol esterification (p < 0.0001), HSP70 (p < 0.0001) and skin unesterified 
cholesterol (p = 0.0006). Cholestane‑triol levels were significantly higher in individuals with NPC versus healthy indi‑
viduals (p = 0.008) and correlated with the 5‑domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411). 
The 5‑domain NPCCSS showed high ICC agreement in inter‑rater reliability (ICC = 0.995) and intra‑rater reliability 
(ICC = 0.937).
Conclusions: Progression rates observed were consistent with other reports on disease progression in NPC. The 
5‑domain NPCCSS reliability study supports its use as an abbreviated alternative to the 17‑domain NPCCSS that 
focuses on the most relevant domains of the disease. The data support the use of cholestane‑triol as a disease 
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Background
Niemann–Pick disease type C (NPC) is a rare, progres-
sive, neurodegenerative disease caused by autosomal 
recessive mutations in either the NPC1 (~ 95% of cases) 
or the NPC2 (~ 5% of cases) gene [1, 2]. The gene prod-
ucts, NPC1 and NPC2, are lysosomal/endosomal pro-
teins, responsible for intracellular lipid transport and 
homeostasis [1, 3–5]. NPC is a disease characterized by 
lysosomal dysfunction, which leads to accumulation of 
lipids such as unesterified cholesterol and sphingolipids 
in the late lysosomal/endosomal compartments within 
multiple organs, predominantly the liver, spleen, lungs 
and brain [1, 6].
Overall, the clinical presentation of NPC varies 
widely and depends on age of onset of neurologi-
cal symptoms [1, 7, 8]. Individuals with early infantile 
onset NPC frequently have isolated hepato-splenomeg-
aly and cholestatic jaundice, whereas individuals with 
a later onset are more likely to have moderate or sub-
clinical organomegaly [1]. As NPC disease advances, 
progressive and severe neurological symptoms develop 
that affect gross motor skills, swallowing ability cogni-
tive functions [7], and life expectancy is shortened [1, 7, 
9–11]. Phenotypes are categorized by the age of onset 
and the progression rate of neurological symptoms: the 
severe and lethal early–infantile and late–infantile phe-
notypes are most often associated with the presence of 
functional null mutations, in which loss-of-function, 
frameshift, splicing or premature stop mutations on 
both alleles of NPC1/NPC2 result in a non-functional 
translation product [12]. Individuals with juvenile and 
adult NPC phenotypes generally carry missense muta-
tions on at least one allele [12].
In rare diseases, real-world data on the features and 
natural progression of a disease and the frequency of 
associated adverse events (AEs) and comorbidities are 
important to understand and information from non-
therapeutic and observational studies can therefore help 
guide the design of clinical trials [13]. This is also the case 
in NPC, where a better understanding of natural history 
and genotypic and phenotypic variability might aid in the 
design of clinical trials.
A clinical staging system for NPC was first proposed in 
1992 based on a small group of intensely studied patients 
but was never widely adopted [14]. In 2006, a 4-domain 
scale was developed from the analysis of a cohort of 30 
individuals with NPC; subsequent scales have built on 
this original work, with varying modifications [15]. The 
17-domain NPC Clinical Severity Scale (NPCCSS), a 
measure of NPC disease severity and progression, was 
introduced in 2010, based on a cohort of 18 then-cur-
rent individuals with NPC and 19 historical cases from a 
study by the National Institutes of Health [16]. Although 
this scale has been used in several clinical trials, notably 
Ory et al. [17], it can be difficult to implement in every-
day clinical practice owing to its complexity. In addition, 
several of the domains included in this instrument—sei-
zures, gelastic cataplexy and psychiatric manifestations—
may be influenced by symptomatic treatment and could 
potentially confound studies of disease-modifying agents. 
To reduce variability and increase the suitability for use 
in clinical trials, an abbreviated version of the 17-domain 
NPCCSS was developed comprising five domains (the 
5-domain NPCCSS) selected by individuals with NPC, 
their caregivers and NPC experts as the most clinically 
relevant domains [18]. These five domains are ambula-
tion, cognition, fine motor skills, speech and swallowing 
(Fig.  1). Although a high correlation (Spearman’s cor-
relation coefficient = 0.93) has previously been found 
between the 5-domain NPCCSS and the 17-domain 
NPCCSS [18], there is a need to provide better support 
for the performance of this revised tool in assessing 
NPC disease severity and progression. Therefore, as part 
of the validation process, to assess the reliability of the 
5-domain NPCCSS as a useful measure and endpoint in 
clinical studies, a study was performed to determine the 
accuracy of the measurements between raters (inter-rater 
reliability) and within raters (intra-rater reliability over 
time) [19, 20].
In addition to the development of tools to measure 
NPC disease progression, diagnostic tests of NPC have 
also evolved over time [21]. Lysosomal lipid accumula-
tion has traditionally been used for diagnostic purposes 
for decades, using analysis of unesterified cholesterol by 
monitoring biomarker and the novel methods of measuring unesterified cholesterol could be applicable to sup‑
port NPC diagnosis. Levels of HSP70 in individuals with NPC were significantly decreased compared with healthy 
individuals.
Trial registration: CT‑ORZY‑NPC‑001: ClincalTrials.gov NCT02435030, Registered 6 May 2015, https ://clini caltr ials.
gov/ct2/show/NCT02 43503 0; EudraCT 2014–005,194‑37, Registered 28 April 2015, https ://www.clini caltr ialsr egist 
er.eu/ctr‑searc h/trial /2014‑00519 4‑37/DE. OR‑REL‑NPC‑01: Unregistered.
Keywords: Lysosomal storage disease, Niemann–Pick type C (NPC) disease, Observational study, NPC Clinical 
Severity Scale (NPCCSS), Heat shock protein, Reliability, Cholestane‑triol, Biomarkers, Natural history of disease
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filipin staining of cultured patient fibroblasts as a static 
marker of lipid storage burden [1, 21]. Traditionally, fil-
ipin staining, which highlights the accumulation of unes-
terified cholesterol, requires cultured patient fibroblasts 
and expert interpreters [21]. Although filipin staining is 
an invasive procedure that is laborious and time-con-
suming, with poor specificity and sensitivity, it remains 
the gold standard method of diagnosis [21], especially 
when genetic testing yields variants of unknown sig-
nificance. The increase in unesterified cholesterol in the 
late endosome/lysosome further leads to the generation 
of oxidated cholesterol derivatives in the serum of indi-
viduals with NPC. Some of these oxidated cholesterol 
derivatives, like cholestane-3β,5α,6β-triol (cholestane-
triol), have been demonstrated to aid diagnosis of NPC 
and cholestane-triol levels correlate with NPC disease 
severity and age of NPC disease onset [22]. Defects in the 
transport of unesterified cholesterol to the endoplasmic 
reticulum for esterification reduces cholesterol esterifi-
cation in skin fibroblasts of individuals with NPC com-
pared with healthy individuals. Cholesterol esterification 
has been proposed to reflect NPC protein function and 
might therefore be used as a diagnostic biomarker for 
NPC [23–25].
In contrast to the established biomarkers of NPC, less 
is currently understood about the role of the heat shock 
response (HSR) in individuals with NPC. The HSR, reg-
ulated by the heat shock factor 1 (HSF1) transcription 
factor, is part of a natural cellular defence mechanism 
against stress-induced protein misfolding, protein home-
ostasis disruption and lysosomal dysfunction [9, 26]. 
HSP70, the most highly expressed heat shock protein 
(HSP) under cellular stress, promotes protein refolding 
and lysosomal function through its interactions with the 
lysosomal sphingolipid metabolic pathways [9, 27–34]. 
Specifically, HSP70 has been shown to aid the maturation 
of both wild type and missense mutated NPC1 [28]. An 
insufficient HSR has been associated with chronic neu-
rological diseases that involve the accumulation of mis-
folded proteins and disturbed cellular homeostasis [26, 
35–37]. HSP70 and active HSF1 levels are reduced in the 
brain of Npc1−/− mice, potentially linking the HSR to 
aberrant lysosomal function [27]. Correlations between 
improved Purkinje cell survival rates and the presence 
of HSPs in central and nodular cerebellar zones have 
also long been recognized in mice [28, 38]. The HSR and 
HSP70, in particular, represent significant potential as a 
therapeutic target for NPC; therefore, the characteriza-
tion of HSP70 expression levels in individuals with NPC 
during the study was of interest.
Aims
To understand disease progression patterns in individu-
als with NPC based on the 5-domain NPCCSS, a pro-
spective, observational study was conducted. The study 
also aimed to characterize novel biomarkers associated 
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Fig. 1 Sub‑domains of the 5‑domain and 17‑domain Niemann–Pick type C Clinical Severity Scale. These are the five domains selected by 
individuals with NPC, their caregivers and NPC experts as the most clinically relevant domains. NPC: Niemann–Pick disease type C; NPCCSS: NPC 
Clinical Severity Scale
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with the altered NPC1/2 protein function and lipid 
metabolism in NPC disease, monitoring their expression 
longitudinally, in order to establish a set of biomarkers 
for NPC and for interventions targeting the HSP sys-
tem in NPC (Orphazyme protocol number: CT-ORZY-
NPC-001; ClinicalTrials.gov ID: NCT02435030) [39].
Additionally, to assess inter- and intra-rater reli-
ability of the 5-domain NPCCSS as a measure of dis-
ease severity in individuals with NPC, the agreement 
between 5-domain NPCCSS total scores and individual 
items was evaluated (Orphazyme protocol number: 
OR-REL-NPC-01).
Results
As described in the Methods, two studies were con-
ducted: the prospective, multicentre observational study 
(CT-ORZY-NPC-001) to measure disease progression 
on the 5-domain NPCCSS and NPC disease biomarkers; 
and the reliability study to assess the inter- and intra-
rater reliability of the 5-domain NPCCSS score (OR-
REL-NPC-01). The results of these studies are presented 
below.
Observational study (CT‑ORZY‑NPC‑001)
Study participants
Thirty-six individuals were enrolled in the study across 
12 clinical sites in seven countries; 31 individuals com-
pleted the study (Fig.  2) over the observation period of 
6–14  months. All individuals had confirmed mutations 
of the NPC1 gene. There were five withdrawals from 
the study for the following reasons: one protocol viola-
tion; one lost to follow-up; one international relocation; 
one discontinuation due to NPC deterioration; and one 
early withdrawal for unknown reasons. The participant 
who withdrew early owing to the international reloca-
tion still had an end-of-trial visit and provided data for 
the assessments (Fig.  2). The mean (± standard devia-
tion [SD]) length of follow-up time for all individuals was 
10.2 months (± 3.1).
The mean age of the population was 9.9  years 
(SD ± 4.6); individuals were aged 2–18 years; the major-
ity of the population was Caucasian (33/36; 91.7%) and 
58.3% (21/36) were female. With regard to phenotype 
characterization, 16.7% (6/36) presented with early–
infantile onset (< 2  years old), 52.8% (19/36) presented 
with late–infantile onset (2– < 6  years old) and 30.6% 
(11/36) presented with juvenile onset (6– < 15 years old). 
The mean (± SD) time elapsed since first NPC symptom 
was 6.7  years (± 3.7) and the mean time elapsed since 
diagnosis was 5.3 years (± 3.4) (Table 1).
Regarding baseline disease characteristics, the most 
commonly reported neurological symptoms, provided 
by referring clinicians as current medical conditions, was 
ataxic clumsiness/impaired coordination (31/36; 86.1%), 
and vertical supranuclear gaze palsy (29/36; 80.6%). In 
the clinician assessments, the specific term of ataxia was 
only listed for 2 of 36 individuals (5.6%); however, when 
assessed using the NPC-cdb tool, ataxia was found to be 
present in 28 individuals (77.8%). Additionally, comor-
bid neurological disorders were reported in 11 of the 
36 individuals (30.6%) under the preferred terms of epi-
lepsy (5/36; 13.9%), cataplexy (2/36; 5.6%), seizure (2/36; 
5.6%), hypotonia (1/36; 2.8%) and resting tremor (1/36; 
2.8%). Miglustat was being administered as part of rou-
tine clinical care in 30 of the 36 individuals (83.3%), and 
9 individuals (25.0%) were receiving concomitant anti-
epileptic medication (lamotrigine, levetiracetam and/or 
topiramate).
Clinical progression
At Visit 1, the mean (± SD) baseline disease sever-
ity scores were 9.6 (± 6.0) for the 5-domain NPCCSS 
and 16.7 (± 9.6) for the 17-domain NPCCSS. The mean 
(± SD) increase in the total 5-domain NPCCSS was 1.4 
(± 2.9), representing a mean (± SD) change per 6 months 
of 0.75 (± 1.58; annualized progression = 1.5 points) 
(Fig.  3a). Except for cognition, each of the individual 
five domains showed an increase in score from Visit 1 to 
Visit 2 (Fig. 3b). For the 17-domain NPCCSS, there was a 
mean (± SD) increase of 2.7 (± 4.0), representing a mean 
(± SD) change per 6 months of 1.47 (± 2.25).
Disease progression was also evidenced using the NPC 
clinical database (NPC-cdb) score, for which the baseline 
All enrolled 
participants
(N = 36)
All participants
(n = 39)
Screen failures
(n = 3)
Completed
(n = 31)
Early withdrawal
(n = 5)
• Protocol violation (n = 1)
• Lost to follow-up (n = 1)
• Moved abroad (n = 1)
• Deterioration (n = 1)
• Unknown (n = 1)
Fig. 2 Participant flow diagram. N = overall number of enrolled 
participants; n = number of participants per category. One participant 
who withdrew early had an end‑of‑trial visit and is included in 
efficacy assessments
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Table 1 Participant demographics and disease characteristics (all enrolled participants)
NPC: Niemann–Pick disease type C; NPC-cdb: NPC clinical database; SD: standard deviation
Demographic data All individuals (N = 36)
Age, years Mean (SD) 9.9 (4.6)
Median 9.5
Range 2.0–18.0
Sex, n (%) Male 15 (41.7%)
Female 21 (58.3%)
Ethnicity, n (%) Caucasian 33 (91.7%)
Asian 1 (2.8%)
Other 2 (5.6%)
Height, cm Mean (SD) 134.1 (24.9)
Median 136.0
Range 82.0–176.0
Height‑for‑age Z score Mean (SD) − 0.14 (1.36)
Median 0.06
Range (− 3.38–2.67)
Weight, kg Mean (SD) 34.63 (15.57)
Median 32.35
Range 10.00–71.70
Body mass index, kg/m2 Mean (SD) 18.0 (2.6)
Median 18.0
Range 14.1–23.1
Age at first NPC symptom, years Mean (SD) 3.8 (3.4)
Median 3.0
Range 0.0–14.0
Phenotype characterization, n (%) Early–infantile onset (< 2 years old) 6 (16.7%)
Late–infantile onset (2– < 6 years old) 19 (52.8%)
Juvenile onset (6– < 15 years old) 11 (30.6%)
Time since first NPC symptom, years Mean (SD) 6.7 (3.7)
Median 6.4
Range 1.7–15.8
Time since NPC diagnosis, years Mean (SD) 5.3 (4.0)
Median 3.5
Range 0.2–15.8
Currently treated with miglustat, n (%) Yes 30 (83.3%)
No 6 (16.7%)
Historic NPC‑cdb score Mean (SD) 40 (21)
Median 38
Range 4–91
Fig. 3 5‑domain NPCCSS scores at Visit 1 and Visit 2. a Mean (SD) overall scores at Visit 1 and Visit 2 for all participants.* b Change in overall scores 
from Visit 1 to Visit 2 by length of follow‑up time. c Mean (SD) individual scores for the five key sub‑domains at Visit 1 and Visit 2, with mean change. 
NPCCSS: Niemann–Pick disease type C Clinical Severity Scale; SD: standard deviation. *One participant who withdrew early had relocated, but had 
an end‑of‑trial visit and is included in efficacy assessments. According to the statistical analysis plan, the NPC‑001 study ended at a study site once 
the interventional NPC‑002 study commenced at that specific site. The NPC‑002 study had not started at the site of this particular participant when 
they relocated, therefore the end of study visit was planned (prior to completion of the study). The participant had a planned withdrawal visit after 
162 days. Of the study withdrawals, only this participant had an end of study visit. Their screening visit and end of study visit are therefore included 
as per statistical analysis plan
(See figure on next page.)
Page 6 of 18Mengel et al. Orphanet J Rare Dis          (2020) 15:328 
Visit 1 (n = 36)
Visit 2 (n = 32)
2.0 2.7 2.0 1.6 1.22.2 2.7 2.5 2.0 1.4
9.6 10.7
0
5
10
15
20
25a
b
c
Visit 1 (n (2tisiV)63= n = 32)
D
is
ea
se
 s
ev
er
ity
(5
-d
om
ai
n 
N
P
C
C
S
S
 s
co
re
)
0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
0
10
5
15
20
25
D
is
ea
se
 s
ev
er
ity
 (5
-d
om
ai
n 
N
P
C
C
S
S
 s
co
re
)
Follow-up time (days)
Change Ambulation Cognition Fine motor skills Speech Swallowing
Mean (SD) 0.3 (0.7) 0.0 (0.6) 0.4 (1.1) 0.3 (0.9) 0.4 (0.9)
Median 0.0 0.0 0.0 0.0 0.0
–1.0 to 2.0 –1.0 to 3.0 –1.0 to 4.0 –2.0 to 3.0 –1.0 to 3.0Range
0
1
2
3
4
5
D
is
ea
se
 s
ev
er
ity
 (s
ub
-d
om
ai
n 
N
P
C
C
S
S
 s
co
re
)
Page 7 of 18Mengel et al. Orphanet J Rare Dis          (2020) 15:328  
score (± SD) was 39.4 (± 20.0) and there was a mean (± SD) 
increase of 5.0 (± 7.9). Using the Pareto principle for evalu-
ation of the EuroQol 5-Dimension 3-Level Youth Proxy 
version questionnaire (EQ-5D-3L Y) assessment tool, of the 
30 individuals who completed repeat assessment, 12 indi-
viduals (40.0%) had a worse score at Visit 2 compared with 
Visit 1 and 7 (23.3%) each had a better score or an equal 
score at Visit 2 compared with Visit 1 (Table 2).
Genotype analysis
Based on historical genotype examinations of the Clin-
Var and NPC-db2 databases [40], there were 34 distinct 
previously reported alleles and 8 distinct unreported 
mutation alleles of the NPC1 gene, within the study 
population of 36 enrolled participants. Most arose from 
substitution mutations at the DNA level (87.5%; n = 63 
alleles), which in most cases resulted in missense muta-
tions at the protein level (76.4%; n = 55 alleles) (Table 3). 
For two mutations, the change on the protein level could 
not be determined. Functional null mutations, such as 
frameshift, splicing or premature stop mutations, were 
present in 20.8% (n = 15) of alleles; one individual had a 
double functional null mutation: A1108fs/A1108fs. This 
individual was 2.5 years old at enrolment and exhibited a 
severe disease progression of 14 points during an obser-
vation period of 13 months.
Biomarkers
Values at Visits 1 and 2, changes in parameters per 
6 months, and values for healthy individuals for all bio-
markers are presented in Table 4 and Fig. 4.
Unesterified cholesterol levels in the skin biopsy sam-
ples were numerically decreased from Visit 1 to Visit 2 
(p = 0.1748), with a mean (± SD) change in parameter 
per 6  months of –0.23  μg/mg skin (± 0.47). Moreover, 
equivalent measurements in a cohort of healthy individu-
als (n = 6) of 0.36 μg/mg skin (± 0.14) were significantly 
lower compared with individuals with NPC (p = 0.0006; 
Table 4, Fig. 4b). This result demonstrates that unesteri-
fied cholesterol measured by LC–MS/MS in skin can be 
successfully used as a novel method to measure choles-
terol burden. In PBMCs, unesterified cholesterol lev-
els were numerically increased between Visits 1 and 2 
(p = 0.8015) and showed a mean (± SD) change in param-
eter per 6  months of 25.94  μg/mg protein (± 97.56); 
equivalent measurements in a cohort of healthy individu-
als (n = 6) of 76.39  ng/mg protein (± 33.82) were also 
numerically lower compared with individuals with NPC 
(Table 4, Fig. 4c). However, there was considerable vari-
ability in the study population owing to the presence of 
two outliers distorting the summary statistics. There were 
no significant correlations found between disease sever-
ity as measured by the 5-domain NPCCSS and either skin 
or PBMC unesterified cholesterol (Fig. 5a, b).
Mean (± SD) serum cholestane-triol levels in indi-
viduals with NPC at both Visits 1 and 2 (88.31 ng/mL 
[± 28.66] and 88.52 [± 31.56], respectively) were sig-
nificantly higher than the mean (± SD) serum choles-
tane-triol levels of 5.97  ng/mL (± 1.13) observed in a 
cohort of healthy individuals (n = 3; p = 0.008). There 
was also a numerical increase between Visits 1 and 2 
(p = 0.3069), with a mean (± SD) change per 6 months 
of 2.64  ng/mL (± 10.69). These findings are consist-
ent with those previously published elsewhere in the 
literature [22, 41] (Table  4, Fig.  4d). Furthermore, 
cholestane-triol levels correlate (Spearman’s correlation 
coefficient = 0.265, p = 0.0411) with 5-domain NPCCSS 
scores (Fig. 5c).
Cholesterol esterification levels in PBMC, a meas-
ure of the NPC protein functionality, were numeri-
cally increased from Visit 1 to Visit 2 (p = 0.1212), 
Table 2 Pareto principle classifications for  evaluation 
of the EQ-5D-3L Y from Visit 1 to Visit 2
EQ-5D-3L Y: EuroQol 5-Dimension 3-Level Youth Proxy version questionnaire
Classification Number of individuals 
(n = 30)
Better (at least one dimension has improved, 
and no worsening is seen in any other 
dimension), n (%)
7 (23.3%)
Worse (at least one dimension has worsened, 
and no improvements are seen in any other 
dimension), n (%)
12 (40.0%)
Same (the health profiles are the same; there 
has been no change in health state), n (%)
7 (23.3%)
Mixed (the dimensions are better on one 
dimension, but worse on another), n (%)
4 (13.3%)
Table 3 Summary of  genotypic data from  72 alleles in  36 
enrolled individuals
NPC: Niemann–Pick disease type C
NPC alleles (n = 72)
Total number of different alleles 42
 Known mutations 34
 New mutations 8
DNA level mutations
 Deletion 4 (5.6%)
 Insertion 5 (6.9%)
 Substitution 63 (87.5%)
Protein level mutations
 Frameshift 9 (12.5%)
 Missense 55 (76.4%)
 Splice 3 (4.2%)
 Stop codon 3 (4.2%)
 Unknown 2 (2.8%)
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and showed a mean (± SD) change per 6  months of 
57.41 ng/mg protein (± 303.81). This analytical method 
was originally described by Vanier in 1988 and has 
been used in support of NPC diagnosis [25]. Choles-
terol esterification levels in samples from those with 
NPC were significantly lower than those from a cohort 
of healthy individuals (n = 37; p < 0.0001), reflecting the 
reduced NPC protein function in individuals with NPC 
(Table 4, Fig. 4e). There were no significant correlations 
found between disease severity and cholesterol esterifi-
cation (Fig. 5d).
Across the study population, mean (± SD) HSP70 
expression levels changed from Visit 1 (1804.09  pg/
mL [± 713.67]) to Visit 2 (1469.94  pg/mL [± 581.21]; 
p = 0.0121), and had a mean (± SD) change per 6 months 
of –225.36  pg/mL (± 411.76). In all but one individual, 
HSP70 expression levels were significantly decreased 
in PBMCs of the individuals with NPC compared with 
those observed in a cohort of healthy individuals (n = 19; 
p < 0.0001) (Table  4, Fig.  4f ). There were no significant 
correlations found between disease severity and HSP70 
(Fig. 5e).
Adverse events
There were 120 AEs occurring in 25 of 36 individuals 
(61.1%); most of these AEs were mild to moderate in 
severity. The majority of AEs were classed as infec-
tions (18/36 individuals; 50.0%), with the most com-
mon being rhinitis (8/36, 22.2%). Epilepsy accounted 
for two AEs in one of 36 individuals (2.8%). There 
were five serious adverse events (SAEs) that occurred 
in three individuals; all of these SAEs were infections. 
No AEs or SAEs resulted in death or discontinuations 
(Table 5).
Reliability study of the 5‑domain NPCCSS (OR‑REL‑NPC‑01)
A total of four video recordings of individuals with 
NPC were used in the reliability study that was part of 
the validation process of the 5-domain NPCCSS. The 
videos represented a wide range of disease severities 
5-domain NPCCSS scores (mean values ranged from 
4.46 to 18.85; Table 6) and ages (8, 10, 12 and 17 years). 
To assess inter- and intra-rater reliability of the 
5-domain NPCCSS, a group of 13 NPC expert clinicians 
provided initial and repeat ratings of the four videos, 
with at least a 3-week interval between repeat ratings. 
The resulting intraclass correlation coefficients (ICCs) 
were high between the initial and repeat time points 
(intra-rater reliability ICC = 0.937), as well as between 
clinicians (ICC = 0.995). For the individual domains, 
the coefficients were above 0.70 for all domains at the 
initial time point (range 0.763–0.954). At the repeat 
time point, ambulation fell slightly below the criterion 
threshold (coefficient of concordance = 0.681), with 
all other domains above the criterion threshold (range 
0.723–0.949) (Table 6).
As a sensitivity analysis, an evaluation of the clinician 
ratings using item-response theory analyses was con-
ducted using participant videos and 5-domain NPCCSS 
scores, which indicated strong agreement across the cli-
nician group (57.6% exact agreement; 0.87 correlation 
Table 4 Change in  disease biomarkers over  the  6–14-month observation period compared with  those of  healthy 
individuals
* Comparisons between visits utilized the Wilcoxon–Mann–Whitney test. Comparisons between individuals with NPC and healthy individuals utilized the Wilcoxon 
signed-rank test
HSP70: heat shock protein 70; PBMC: peripheral blood mononuclear cell; SD: standard deviation
Skin unesterified 
cholesterol (μg/mg 
skin)
PBMC unesterified 
cholesterol (μg/mg 
protein)
Serum 
cholestane‑
triol (ng/mL)
PBMC cholesterol 
esterification (ng/mg 
protein)
PBMC HSP70 (pg/mL)
Visit 1, n 26 30 28 35 28
Mean (± SD) 2.79 (± 0.96) 77.56 (± 21.53) 88.31 (± 28.66) 462.14 (± 283.60) 1804.09 (± 713.67)
Visit 2, n 14 28 32 28 24
Mean (± SD) 1.89 (± 0.64) 98.45 (± 99.56) 88.52 (± 31.56) 616.89 (± 443.10) 1469.94 (± 581.21)
p value for the comparison 
between visits*
0.1748 0.8015 0.3069 0.1212 0.0121
Change in parameter per 
6 months, n
11 23 26 27 20
Mean (± SD) –0.23 (± 0.47) 25.94 (± 97.56) 2.64 (± 10.69) 57.41 (± 303.81) –225.36 (± 411.76)
Healthy individuals, n 6 6 3 37 19
Mean (± SD) 0.36 (± 0.14) 76.39 (± 33.82) 5.97 (± 1.13) 1197.15 (± 763.65) 12,310.21 (± 4247.23)
p values compared with 
healthy individuals*
0.0006 0.8979 0.008  < 0.0001  < 0.0001
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across ratings; sample error = 0.04). More specifi-
cally, this evaluation used the Many-Facets item analy-
sis, an extension of Rasch measurement models for 
rater-mediated data [42]. In terms of the fit of the partici-
pant videos, all videos fit the model, none were misfitting 
(infit value ≥ 1.5; range 0.76–1.11) and the correlation 
across ratings was 0.73 with an error rate of 0.02. For the 
individual domains, there were no misfitting domains 
(infit value ≥ 1.5; range 0.72–1.16) and the correlation 
across ratings was 0.85 with an error rate of 0.01.
Additionally, in the rating scale analysis, conducted 
using the same Many-Facets model, monotonic increases 
in severity rating from lowest (verbal response option = 0; 
average person measure = − 4.59) to most severe (ver-
bal response option = 5; average person measure = 3.53) 
were observed. Agreement between the participant 
severity ratings was observed between the classical 
descriptive statistics (ICC) on the 5-domain NPCCSS 
and the item-level Many-Facets analysis. Facets meas-
ures were as follows: participant C = 3.30 (most severe); 
participant B = 0.22; participant A = − 1.32; participant 
D = − 2.20 (least severe) (Table 7).
Discussion
In the field of rare diseases, prospective observational 
studies are vital for establishing patterns of disease pro-
gression and to help inform and shape relevant outcome 
measures for future clinical trials [43]. In this prospective, 
observational cohort study of NPC, the disease severity 
of the study population worsened from Visit 1 to Visit 2; 
this applies to all the clinical scores assessed (5-domain 
NPCCSS, 17-domain NPCCSS and NPC-cdb). The mean 
(± SD) change on the 5-domain NPCCSS at 6  months 
was 0.75 (± 1.58), corresponding to an annualized disease 
progression of 1.5 within the cohort. The mean (± SD) 
change on the 17-domain NPCCSS at 6 months and the 
mean (± SD) overall change on the NPC-cdb were 1.47 
(± 2.25) and 5.0 (± 7.9), respectively. The findings from 
the NPC-001 study therefore support the characteriza-
tion of NPC as a heterogenous, progressive neurodegen-
erative disease.
Table 5 Summary of  adverse events and  serious adverse 
events (all enrolled participants)
EBV: Epstein–Barr virus
Number 
of individuals 
(N = 36)
Adverse events ‑
Total 25 (69.4%)
 Mild 23 (63.9%)
 Moderate 15 (41.7%)
 Severe 5 (13.9%)
Most common adverse events experienced by > 5% of 
participants
‑
 Rhinitis 8 (22.2%)
 Diarrhoea 7 (19.4%)
 Pyrexia 6 (16.7%)
 Nasopharyngitis 5 (13.9%)
 Bronchitis 3 (8.3%)
 Gastroenteritis 2 (5.6%)
 Cough 2 (5.6%)
 Vomiting 2 (5.6%)
 Hepatomegaly 2 (5.6%)
 Pharyngitis 2 (5.6%)
 Skin infection 2 (5.6%)
 Pain in extremities 2 (5.6%)
 Headache 2 (5.6%)
 Serious adverse events
Total 3 (8.3%)
 Wound infection 2 (5.6%)
 Streptococcus infection 1 (2.8%)
 Scarlet fever 1 (2.8%)
 EBV infection 1 (2.8%)
 Discontinuations owing to adverse events 0 (0.0%)
Table 6 Item-level coefficient of concordance for the 5-domain 
NPCCSS
Kappa coefficients of concordance for initial and repeat ratings for each domain
NPCCSS: Niemann–Pick type C disease Clinical Severity Scale
Domain Kappa coefficient of concordance
Initial rating Repeat rating
Ambulation 0.785 0.681
Cognition 0.917 0.883
Fine motor skills 0.763 0.723
Speech 0.954 0.949
Swallowing 0.813 0.858
Table 7 Mean 5-domain NPCCSS score by  participant 
videos
* Facets measures were as follows: participant C = 3.30 (most severe); participant 
B = 0.22; participant A = –1.32; participant D = –2.20 (least severe)
NPCCSS: Niemann–Pick type C disease Clinical Severity Scale
Participants* MEAN 5‑domain NPCCSS score (± SD)
Initial rating Repeat rating
Participant A 5.85 (2.115) 7.00 (1.633)
Participant B 11.08 (2.326) 10.46 (1.713)
Participant C 18.15 (1.772) 18.85 (1.068)
Participant D 4.46 (1.391) 4.77 (2.204)
p value  < 0.0001  < 0.0001
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The use of the 5-domain NPCCSS has previously been 
supported by Cortina-Borja et  al. 2018 [18]. The study 
reported that these five domains (ambulation, cognition, 
fine motor skills, speech and swallowing) were deter-
mined by individuals with NPC, caregivers and clinicians, 
to be the most clinically relevant and were highly cor-
related with the total 17-domain NPCCSS (Spearman’s 
correlation coefficient = 93%) [18]. The findings from the 
Cortina-Borja et  al. cohort indicate that the 5-domain 
NPCCSS reflects disease progression measured by the 
17-domain NPCCSS; further work is underway to vali-
date and to confirm the patients and clinicians view on 
clinical meaningful changes on the 5-domain NPCCSS 
and is documented in the NPC Patient-Focused Drug 
Development report to the Food and Drug Administra-
tion [44].
Disease progression observed on the 17-domain NPC-
CSS was consistent with other NPC populations. In 
the population studied by Ory et  al. [17], the change 
in disease progression per 12  months on the over-
all 17-domain NPCCSS was 2.92 (standard error of the 
mean [SEM] = 0.27), which is consistent with the mean 
(± SD) reported progression rate per 6  months in this 
current study of 1.47 (± 2.25) of a heterogeneous study 
population. As mentioned in the introduction, a poten-
tial confounder of the 17-domain NPCCSS is its com-
plexity and the inherent difficulty of its implementation 
in everyday clinical practice. The 5-domain abbreviated 
scale has practical benefits in improving time efficiency, 
minimizing statistical variability, and reducing influ-
ence from disease manifestations that can cause general 
clinical fluctuations such as seizures and respiratory 
complications.
NPC disease severity and complications may also 
fluctuate day to day in individuals with NPC, although 
this confounder is minimized by the format of the 
5-domain NPCCSS, which means that no single domain 
can be deemed the most important. As a total score, 
the 5-domain NPCCSS captures the impact of NPC 
on patients’ functioning, so that each step on the score 
reflects a considerable change in function. The 5-domain 
NPCCSS total score differs from tools developed to 
assess subtle changes in different domains, such as neu-
ropsychological batteries used to assess potential cogni-
tive impairment, the Scale for Assessment and Rating for 
Ataxia [45], the 9-Hole Peg Test for fine motor changes 
[46], and the 3-min stair climb test for ambulation. 
Although these cognitive evaluations have been validated 
in other disease populations, they are not disease specific 
and there are not enough data on their specificity and 
sensitivity regarding rates of change in NPC populations.
Missense mutations in NPC1 are the most common 
type of mutation reported in NPC (75% of patient alleles) 
[12]; this was also the case in this study. As in most lys-
osomal storage diseases, a clear genotype/phenotype 
relationship is difficult to establish in NPC [47, 48], and 
it was not possible to correlate the biomarker and pro-
gression values reported here to specific mutations in a 
meaningful way. One exception was a patient homozy-
gous for the A1108fs frameshift mutation, who exhibited 
a disease progression of 14 points in 13 months, confirm-
ing that double functional null genotypes are highly pre-
dictive of a severe and early progressive disease course 
[12, 47]. Other NPC cohorts of similar sizes have also 
reported individuals with double functional null geno-
types occurring at similar rates within representative, 
heterogenous populations [49, 50]; therefore, the occur-
rence of this genotype in the current study is not unex-
pected. A detailed report on the mutations found in this 
study population, and in that of the double-blind inter-
ventional NPC-002 study, will be explored further in a 
separate publication.
This study aimed to characterize novel NPC disease 
biomarkers in order to establish a set of biomarkers for 
NPC that are focused on interventions targeting the HSP 
system in NPC and the underlying cellular pathology of 
NPC, including altered NPC1/2 protein function and 
lipid metabolism. During the time of this study and its 
publication, it is worth noting that other biomarkers such 
as lyso-sphingomyelin-509 and bile acids have also shown 
potential as biomarkers of NPC disease [41, 51–53].
Determination of unesterified cholesterol in skin 
biopsy samples showed significantly increased levels 
in individuals with NPC (p = 0.0006) compared with a 
cohort of healthy individuals whose biomarker levels 
were representative of the wider population. Hence, the 
findings confirm that LC–MS/MS-based measurements 
of skin biopsy samples are a valid method to support the 
biochemical diagnosis of NPC [21], and to measure the 
cholesterol storage burden in individuals with NPC. No 
evidence of changes in the storage burden over time were 
observed, nor were any correlations with the 5-domain 
NPCCSS found (Fig. 5a). A limitation of these data was 
that at Visit 2, skin unesterified cholesterol assessments 
were performed on fewer individuals than at Visit 1; a 
minimum of 4 mg skin was required to perform the anal-
ysis, and 16 of 36 skin biopsy samples from Visit 2 did not 
fulfil this requirement. As a result, the repeat assessment 
for these individuals could not be confirmed. Never-
theless, the levels in the NPC individuals here are simi-
lar to those reported previously using similar LC–MS/
MS methods [17]. These findings also demonstrate that 
unesterified cholesterol may be measured directly in skin 
biopsy samples in lieu of isolating and culturing fibro-
blasts for subsequent filipin staining, which is both time 
and labour intensive. This therefore has the potential to 
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shorten the time for diagnosis [21]. To potentially moni-
tor longitudinally unesterified cholesterol levels in indi-
viduals with NPC, the PBMC method has benefits over 
skin biopsy sampling because it eases the sampling bur-
den on the individual, especially within the young NPC 
demographic, and may reduce variability.
In clinical practice, cholestane-triol is frequently used 
as a biomarker to support diagnosis [7]. In this trial, 
cholestane-triol levels are similar to those reported in 
other NPC cohorts at diagnosis [23, 41]. An increase 
over 6  months in cholestane-triol levels was observed 
with a mean (± SD) change per 6 months of 2.64 ng/mL 
(± 10.69), and cholestane-triol levels were significantly 
correlated (Spearman’s correlation coefficient = 0.265, 
p = 0.0411) at the population level with disease severity 
on the 5-domain NPCCSS (Fig.  5c). These results con-
firm previous studies demonstrating an increased choles-
tane burden with NPC disease severity [22]. However, 
unlike previous studies, the CT-ORZY-NPC-001 results 
reported here do not support a correlation between 
serum cholestane-triol levels and age of NPC disease 
onset (data on file) [22, 41]. Together these data sup-
port the use of cholestane-triol as a biomarker of disease 
severity in the NPC population as a whole and may be 
useful in the follow-up of an individual patient to poten-
tially monitor disease.
Based on the Vanier 1988 method [25], a new analyti-
cal method for cholesterol esterification in PBMC was 
established, aiming to shorten the time to diagnosis and 
reduce the burden on the individual, while also giving a 
direct measurement of NPC protein function. The find-
ings demonstrate that cholesterol esterification is signifi-
cantly decreased in the PBMCs of individuals with NPC 
compared with healthy individuals (p < 0.0001). Muta-
tions in the NPC genes either result in reduced protein 
function because of limited binding capacity, or reduced 
abundance because of a more rapid degradation of the 
dysfunctional protein [2, 4, 54, 55]; therefore, NPC func-
tion is not expected to change with disease progression. 
Accordingly, no significant change in cholesterol esterifi-
cation was observed during the study, nor did cholesterol 
esterification correlate with disease progression (Fig. 5d). 
Although variation of cholesterol esterification levels in 
PBMC was high, both within and between individuals, 
this was likely owing to the limited viability of PBMCs 
for the analytical method. Nonetheless, the current study 
confirms that PBMCs are a valid matrix on which to 
assess NPC protein function and to potentially support 
NPC diagnosis.
Establishing the basal levels of HSP70 in the PBMCs 
of individuals with NPC and assessing its variability dur-
ing the study was the key intention of measuring HSP70 
expression levels. We have established that HSP70 
expression levels are decreased in individuals with NPC 
compared with those in the cohort of healthy individu-
als, with relatively stable levels over time. These findings 
are consistent with those demonstrated in murine mod-
els where Npc1−/− mice exhibit lower levels of HSP70 
expression and HSF1 activation compared with wildtype 
mice; drug-induced elevated expression of HSP70 in the 
Npc1−/− mouse model was associated with reduction in 
glycosphingolipid accumulation, improvement in CNS 
myelination, improvement in measurable manifestations 
of ataxia and reduced loss of motor coordination [27]. 
Additionally, insufficient induction of HSPs has been 
associated with a variety of chronic neurological diseases 
[26]. The data presented here on HSP70 expression lev-
els in the PBMCs of healthy individuals are in accordance 
with those previously published in Madden et  al. 2010 
[56].
With regard to safety, this was a non-interventional 
study with no investigational medicinal product, and so 
AEs were recorded to inform the background occurrence 
of adverse events in individuals with NPC on routine 
clinical care. Overall, nine of the 120 AEs (7.5%) were 
considered definitely related to NPC disease and eight 
AEs (6.7%; all cases of diarrhoea) were considered to be 
related to miglustat use by the investigators. This high-
lights the importance of ensuring stable routine clinical 
care prior to enrolment.
Among the potential limitations of the NPC-001 obser-
vational study was the high proportion of individuals 
receiving miglustat (30/36; 83.3%). Miglustat is likely to 
modify the clinical progression of NPC [57]. However, 
the nearly ubiquitous use of miglustat across the study 
population meant that subgroup analysis of those not 
receiving miglustat could not be done, and so the effect 
of miglustat use on clinical evolution and disease pro-
gression could not be determined. With regard to the 
baseline disease characteristics as reported by referring 
clinicians as current medical conditions, the specific term 
of ataxia (reported in 2 of 36 individuals [5.6%]) appeared 
to be lower than in other reported NPC populations. 
This is likely because many of the study participants were 
defined non-specifically at baseline as clumsy or unco-
ordinated, rather than given the specific term of ataxic. 
However, from the NPC-cdb tool during baseline study 
assessments, ataxia was found to be present in 28 of 36 
individuals (77.8%); this is in line with both the ambu-
lation domain scores of the current study population 
and with the literature of other reported populations, 
in which it may be present in up to 76% of individuals 
with NPC [1, 10, 58]. Ideally, to optimize an assessment 
of NPC disease progression, the study could have been 
improved by a longer duration and more frequent or 
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intermediary assessments (e.g. 6-monthly) than over the 
6–14-month observation period employed here.
Another study limitation was the lack of standardiza-
tion of skin punch biopsy depth across the clinical study 
sites. Although all analyses were performed by a single 
central laboratory, the biopsy samples were collected 
by different clinicians at different study sites and some 
biopsy samples were not large enough to apply the analy-
sis method. Additionally, this variability was likely also 
influenced by the challenge of acquiring skin biopsy sam-
ples from children, the quality of which is dependent on 
skin thickness and elasticity, which is determined by the 
precise site of biopsy and age of individual.
The reliability study of the 5-domain NPCCSS, con-
ducted to verify the accuracy of the scoring method 
between and within raters, provided additional support 
for the use of the 5-domain NPCCSS. The results sup-
port the use of the 5-domain NPCCSS score as a relia-
ble endpoint in future studies and suggest that clinicians 
were able to rate participants similarly and consistently, 
as well as utilize each of the categorical severity ratings 
in the manner intended. The supportive Many-Facets 
Rasch analysis illustrated that each of the items contrib-
uting to the 5-domain NPCCSS were locally independent 
(i.e. not dependent on responses to other items), and that 
the instrument, in its brevity, is able to target participants 
along the severity continuum with precision.
Conclusions
In this study, the disease course of patients with NPC, a 
severe progressive neurodegenerative disease, was pro-
spectively characterized over a period of 6–14  months 
using clinical measures and biomarkers. In line with pre-
vious reports, disease progression pattern and rate were 
heterogeneous in this population. Most patients exhib-
ited disease progression during the observation period 
as assessed by the 5-domain NPCCSS and by the overall 
17-domain NPCCSS. Notably, the abbreviated version 
showed high correlation with the 17-domain NPCCSS, 
which had similar progression rates to those previously 
reported. These findings confirm the 5-domain NPCCSS 
as a suitable abbreviated outcome measure in NPC that is 
utilized as the primary outcome measure in the ongoing 
interventional clinical trial in NPC (CT-ORZY-NPC-002; 
ClinicalTrials.gov ID: NCT02612129) [59].
In addition, biomarker results indicate that cholestane-
triol may be used as a disease monitoring biomarker 
with the potential to assess biological response to phar-
macological treatment. The results from this study fur-
ther confirmed the relevance of unesterified cholesterol 
and cholesterol esterification in the biochemical diagno-
sis of NPC, independent of disease severity. The finding 
that the levels of HSP70 in individuals with NPC are 
decreased compared with a cohort of healthy individu-
als is particularly interesting given the role of HSP70 in 
ensuring proper NPC1 function [28], and the mecha-
nism of action of arimoclomol. Arimoclomol is an HSP70 
amplifier being evaluated for its efficacy and safety in the 
CT-ORZY-NPC-002 clinical trial in NPC [59]. In that 
trial, HSP70 is measured to assess the pharmacodynamic 
effect of arimoclomol treatment on the heat shock pro-
tein response.
The inter- and intra-rater reliability analysis represent 
a key step in the full validation process. The ongoing vali-
dation work will be published elsewhere once finalized. 
However, based on the data and analyses presented here, 
the 5-domain NPCCSS scale can be considered as a reli-
able outcome measure in other clinical studies.
Methods
Observational study (CT‑ORZY‑NPC‑001)
Study design
This was a prospective, multicentre, observational study 
to establish disease natural history in which individuals 
remained on their routine clinical care. It was performed 
at 12 clinical sites in seven countries over an observation 
period of 6–14  months. Study assessments were per-
formed at screening and enrolment (Visit 1) and up to 
40 weeks later at the end of the study (Visit 2). Telephone 
follow-ups were every 8  weeks. The primary objective 
was clinical progression assessed by the 5-domain and 
17-domain NPCCSS, the NPC-cdb score and a quality-
of-life questionnaire; the secondary objective of this 
study was safety relating to disease progression and 
routine clinical care. Additional exploratory endpoints 
included biomarker analyses of HSP70 in PBMCs, cho-
lesterol esterification in PBMCs, serum cholestane-triol, 
unesterified cholesterol in PBMCs and skin biopsy sam-
ples, and genotype analysis. The study adhered to the 
Declaration of Helsinki, International Conference on 
Harmonization (ICH) and Good Clinical Practice (GCP) 
standards, and applicable local guidelines [60, 61]. The 
study protocol and associated documentation were 
approved by the relevant independent ethics committees 
and/or institutional review boards, and written informed 
consent was obtained at enrolment from either the indi-
vidual or their legal guardian.
Study participants
The inclusion criteria for the study specified that par-
ticipants should be: male or female; aged 2 to 18 years (to 
exclude individuals with severe neonatal onset of disease); 
of any ethnicity; with a genetic diagnosis of either NPC1 
or NPC2; with a body mass index (BMI) Z score of ≥ − 2 
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SD below mean of the age-adjusted population; presenting 
with at least one neurological symptom; able to walk with 
assistance; treated or non-treated with miglustat with sta-
ble dosing for at least 3 months; and, for those applicable, 
receiving adequate contraception. Potential participants 
were excluded if they exhibited: uncontrolled epilepsy; 
severe hepatic or renal insufficiency; historic or planned 
liver transplants; and other severe disease manifestations 
that would inhibit compliance. Potential participants were 
also excluded if they or their legal guardians did not pro-
vide written informed consent.
Clinical progression
Disease progression was assessed by establishing baseline 
characteristics at Visit 1 and calculating both the absolute 
change at Visit 2 and the change in parameter per 6 months 
(change between visits divided by time between visits times 
6 months). The total 17-domain NPCCSS score consists of 
nine major domain scores of 0–5 and eight minor domain 
scores of 0–2. Summation of these 17 domains yields total 
scores that ranged from 0 to 61, with a higher score indi-
cating a more severe clinical impairment.(15) The abbrevi-
ated 5-domain NPCCSS consists of five key domains that 
were determined to be the most clinically relevant to indi-
viduals with NPC, caregivers and clinicians: ambulation, 
cognition, fine motor skills, speech and swallowing. The 
5-domain NPCCSS total score ranges from 0 to 25, with a 
higher score indicating a more severe clinical impairment. 
The NPC-cdb score aims to reflect an individual’s clini-
cal status. It ranges from 0 to 125 and an increase in score 
reflects a reduction in the individual’s abilities [62]. In this 
study, the NPC-cbd score was modified to utilize a simpli-
fied scoring system. Health-related quality of life (QoL) was 
assessed according to the EQ-5D-3L Y questionnaire [63].
Genotype analysis
Genotype analyses were sourced from historical par-
ticipant records and individual alleles were categorized 
according to mutation type.
Biomarkers
Unesterified cholesterol
Whole blood samples were collected in K2-EDTA tubes 
and shipped to the central analysis site for isolation of 
the PBMCs. Pellets of 1 million cells were generated and 
stored at –80 °C. Lipids were extracted followed by deri-
vatization and unesterified cholesterol was quantified by 
LC–MS/MS as per Crosley et  al. 2009 [64]. Skin punch 
biopsy samples were collected using a 3  mm biopsy 
plunger (Miltex 33-32P; Integra LifeSciences, Plainsboro 
Township, NJ, USA) and stored at –80  °C. Lipids were 
extracted followed by derivatization and unesterified 
cholesterol was quantified by LC–MS/MS.
Cholestane‑triol
Serum samples were collected in serum separation tubes 
and immediately separated by centrifugation at each clin-
ical site. Samples were stored at –80  °C and shipped to 
the central analysis site. Cholestane-triol was determined 
by LC–MS/MS.
Cholesterol esterification
Whole blood samples were collected in sodium-heparin 
tubes and shipped at ambient temperature to the cen-
tral analysis site. PBMCs were isolated by application of 
a density gradient and incubated for 48  h with hepta-
decanoic acid (C17). Following cellular esterification of 
cholesterol with the heptadecanoic acid, cholesterol hep-
tadecanoate was quantified by LC–MS/MS.
HSP70
Whole blood samples were collected in K2-EDTA tubes 
and shipped to the central analysis site for isolation of 
the PBMCs. Pellets of 1 million cells were generated and 
stored at –80  °C. Frozen cell pellets were homogenized 
in RIPA buffer with 1% Protease and Phosphatase Inhibi-
tor Cocktail (R0278, P0044, P8340; Sigma-Aldrich, St. 
Louis, MO, USA), centrifuged, and extracts were diluted 
in assay buffer. HSP70 levels were then quantified by 
sandwich enzyme-linked immunosorbent assay (ELISA) 
(DYC1663; Research and Diagnostic Systems, Inc., Min-
neapolis, MN, USA).
All analytical methods were validated and met the 
acceptance criteria for inter-assay accuracy and precision 
at 15% for LC–MS/MS methods and 20% for the ELISA 
assay (sensitive to haemolysis). No interfering peaks were 
detected at the retention time of the internal standard or 
the analytes for the chromatographic assays. No carry 
over was observed.
Safety
All AEs and SAEs were recorded, as were any changes 
in the results of physical examinations, vital signs, elec-
trocardiographic results, and standard haematology and 
clinical chemistry findings.
Statistical analyses
Continuous variables were summarized by descrip-
tive statistics and categorical variables were assessed by 
absolute and relative frequencies; results from the EQ-
5D-3L Y analyses were assessed according to the Pareto 
principle as per Devlin et  al. 2010 [65]. For biomarker 
data, comparisons between visits utilized the Wil-
coxon–Mann–Whitney test and comparisons between 
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individuals with NPC and healthy individuals utilized the 
Wilcoxon signed-rank test; data from healthy individu-
als were representative of those reported in the wider 
healthy population. All statistical analyses were per-
formed using SAS v9.3 (SAS Institute, Cary, NC, USA).
Reliability study of the 5‑domain NPCCSS (OR‑REL‑NPC‑01)
Study design
Four videos with a clinical evaluation of four different 
individuals with NPC were recorded and formed the 
basis of this study. All individuals provided informed 
consent and parental or guardian permissions to use the 
videos. A single medical NPC expert performed a medi-
cal interview and physical examination of each of the four 
individuals; the format of each of the videos was stand-
ardized. Altogether, individuals were selected to rep-
resent a wide range of disease burden. The NPC expert 
evaluated each individual in accordance with a written 
5-domain NPCCSS rater manual, taking into account the 
individual’s age and level of disability.
The four video-recorded clinical evaluations were then 
evaluated by a group of 13 clinician raters to assess inter- 
and intra-rater reliability of the 5-domain NPCCSS. The 
clinicians received standardized training as per the rater 
manual and the training provided in the CT-ORZY-
NPC-001 observational study.
Raters scored each video twice. An initial scoring 
was conducted for each of the four individuals on the 
5-domain NPCCSS and was then repeated in a random 
order, with at least a 3-week interval between repeat 
ratings. The 13 clinicians were blinded to other raters’ 
scores.
Study participants (video recording)
Eligibility for participation was limited to individuals 
with NPC1 (aged 2–18 years) with at least one neurologi-
cal symptom, the ability to walk independently or with 
assistance, and both participant and their caregiver fluent 
in English. Individuals participating in NPC-001 or NPC-
002 clinical trials were ineligible.
Statistical analysis
A power calculation was conducted a priori to esti-
mate the number of raters needed to rate the videos 
in order to derive reliability estimates above the 0.7 
acceptable reliability threshold. To allow for a power 
of approximately 80% to detect within-group consist-
ency and null between-group variability, the targeted 
sample size was 14 raters. In the study, 13 raters were 
recruited, each of them provided initial and repeat rat-
ings for each video, thus constituting the analytical data 
set. Scores provided by each rater on the 5-domain 
NPCCSS (range 0–25) at the second rating were com-
pared with the first rating in order to assess intra-rater 
reliability. A two-way analysis of variance (ANOVA) 
with repeated measures on raters and participants 
was used to calculate inter- and intra-rater reliability 
within a single model for the 5-domain NPCCSS. For 
the individual domains (ambulation, cognition, fine 
motor skills, speech and swallowing), Kendall’s coeffi-
cient of concordance (W) and polychoric correlations 
were evaluated independently for intra-rater reliability. 
For each reliability parameter, the intraclass correlation 
coefficients (ICC2,13) were generated with pre-speci-
fied criteria for both defined as 0.70 (range 0–1.0 with 
a higher threshold reflective of better rater agreement 
and stability) [66]. As a sensitivity analysis to identify 
potential error in the reliability estimates due to rater 
bias, a Many-Facets item-response analysis was con-
ducted, which allows the clinician rating of severity 
to be derived using a standardized scale similar to the 
individual and to the analyzed item (i.e. equating to a 
similar metric) [42].
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